

# Tamoxifen *vs* Tamoxifen plus 13-cis-retinoic acid *vs* Tamoxifen plus Interferon $\alpha$ -2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial

Matteo Dalla Chiesa<sup>1</sup>, Rodolfo Passalacqua<sup>1</sup>, Maria Michiara<sup>2</sup>, Vittorio Franciosi<sup>2</sup>, Francesco Di Costanzo<sup>3</sup>, Giancarlo Bisagni<sup>4</sup>, Roberta Camisa<sup>2</sup>, Sebastiano Buti<sup>1</sup>, Gianluca Tomasello<sup>1</sup>, Giorgio Cocconi<sup>2</sup>, on behalf of the Italian Oncology Group for Clinical Research (GOIRC)

<sup>1</sup>Oncology Division, Hospital of Cremona, Cremona, Italy; <sup>2</sup>Oncology Division, University Hospital of Parma, Parma, Italy; <sup>3</sup>Medical Oncology Unit, Department of Oncology, University Hospital Careggi, Florence, Italy; <sup>4</sup>Medical Oncology Service, Hospital of Reggio Emilia, Reggio Emilia, Italy

**Abstract.** *Aims and background:* To demonstrate the efficacy of 13-cis-retinoic acid (RA) or Interferon  $\alpha$ -2a (IFN  $\alpha$ -2a) with Tamoxifen (TAM) in the treatment of advanced breast cancer. *Methods:* Ninety-nine postmenopausal patients with advanced breast cancer, and a positive or unknown estrogen (ER) or progesterone (PgR) receptor status, were randomised to receive TAM 20 mg/m<sup>2</sup>/day orally (arm A), or TAM plus RA 1 mg/kg/day orally (arm B), or TAM plus IFN  $\alpha$ -2a 3 MU thrice a week intramuscular (arm C). The three treatment groups were well balanced in terms of the main prognostic factors. *Results:* Response was evaluable in 32 of the patients in arm A, 32 in arm B, and 30 in arm C. Intention-to-treat analysis showed no significant difference of response rate in the three arms (44% *vs* 38% *vs* 42%). After an eight years median follow-up, there was no significant between-group difference in median overall survival: 47.4 *vs* 38.2 *vs* 45.1 months. Side effects were negligible in arm A, but cutaneous (39%) and mucosal (62%) toxicities were frequent in arm B, and flu-like syndrome and/or myalgia (46%) in arm C. *Conclusions:* The administration of RA or IFN  $\alpha$ -2a does not add anything to the therapeutic effects of TAM. ([www.actabiomedica.it](http://www.actabiomedica.it))

**Key words:** Tamoxifen, 13-cis-retinoic acid, interferon  $\alpha$ -2a, advanced breast cancer

## Introduction

*In vitro* studies have shown that retinoids inhibit the proliferation of neoplastic cells, particularly breast cancer cells (1), and it has been also observed that the combination of retinoids and tamoxifen (TAM) can have positive effects on the inhibition of cell growth (2). These effects are partially due to the ability of both drugs to stimulate the expression of the negative growth factor TGF- $\beta$  (3). However, clinical studies on the use of retinoids in the treatment of ad-

vanced breast cancer have led to essentially negative results (4), although these involved patients who were refractory to conventional treatments.

It has been long known that, in addition to its antiviral effects, Interferon- $\alpha$  (IFN- $\alpha$ ) shows antineoplastic activity due to immunomodulatory mechanisms, antiproliferative and/or differentiating effects, the inhibition of angiogenesis, interactions with growth factors, and the modulation of gene expression. As a single agent, despite reports that it has a certain degree of activity (5-10), it shows little or no

therapeutic effect in advanced breast cancer (11, 12), but more interesting results have been obtained when it is combined with TAM (13, 14).

The aim of this study was to investigate the efficacy of 13-cis-retinoic acid (RA) or IFN- $\alpha$ 2a when used together with TAM in the treatment of advanced breast cancer.

In a previous work we reported the preliminary results of this trial (15).

Now we present the update with a longer follow-up.

## Patients and methods

The entry criteria of this study of postmenopausal patients with metastatic breast cancer included a histological diagnosis of breast cancer, and age of <75 years, an unknown or positive estrogen and/or progesterone receptor status, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, a life expectancy of  $\geq 3$  months, leukocyte and platelet counts of respectively  $\geq 3.500/\text{mm}^3$  and  $\geq 100.000/\text{mm}^3$ , and creatinemia and bilirubinemia levels of  $\geq 1.5$  mg/dl.

Post-menopause is defined as a period of amenorrhea of at least 12 months in patients aged  $\geq 53$  years or who had undergone ovariectomy; younger patients had to have a period of amenorrhea of at least 12 months and plasma FSH and LH levels of  $>40$  MU/ml.

The patients could have received one or more lines of chemotherapy for advanced disease provided that they showed disease progression and all manifestations of acute toxicity had disappeared. Previous adjuvant endocrine therapy was allowed provided that at least 24 months had passed since its discontinuation; previous adjuvant chemotherapy was allowed regardless of the time since its discontinuation.

Patients who had received previous endocrine therapy for advanced disease were excluded, as were those in whom the only disease manifestation was osteoblastic bone metastasis or pleural/peritoneal effusion. The other exclusion criteria were massive liver metastases or central nervous system metastases; other previous or concomitant malignancies (excluding adequately treated skin carcinoma or *in situ* carcinoma of the uterine neck); heart failure and/or severe symptomatic ischemic heart disease and/or severe arterial hy-

pertension and/or previous thromboembolic episodes; psychic disorders considered as making it difficult or impossible to apply the therapeutic programme.

The study was approved by our Ethics Committee and all of the patients gave their written informed consent.

Upon entry, a medical history was taken, and all of the patients underwent a physical examination, blood chemistry tests, a chest X-ray, bone scintigraphy, skeletal X-ray (except in the case of negative bone scintigraphy results), and liver echography or computed tomography. The patients subsequently underwent a physical examination and laboratory tests every month for the first three months, and then every three months; instrumental evaluations of the lesions present at study entry after three months, and then every three months; and chest X-ray, bone scintigraphy and hepatic echography (if normal at baseline) after six months, and then every six months.

Estrogen and progesterone receptors were measured using the carboxydextrane method in accordance with the guidelines of the European Organisation for Research and Treatment of Cancer (EORTC), or immunohistochemical methods.

Since the study was carried out before the adoption of the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, therapeutic response was evaluated on the basis of the World Health Organisation (WHO) criteria (16).

Three treatment arms were analysed: arm A received conventional treatment with TAM 20 mg/m<sup>2</sup>/day orally in two daily administrations until progression or disease relapse; arm B received the same TAM treatment plus RA 1 mg/kg/day orally in a single daily administration until progression or disease relapse; and arm C received TAM + IFN- $\alpha$ 2a 3 MU intramuscular thrice weekly until progression or disease relapse.

Any dose adjustment due to early side effects could only be made after at least one week of treatment. Dose reductions or the temporary or permanent discontinuation of RA or IFN- $\alpha$ 2a were foreseen on the basis of the degree of toxicity: grade I = no dose reduction; grade II = 50% reduction in RA or 33% reduction in IFN- $\alpha$ 2a; grade III = 75% reduction in RA or temporary discontinuation of IFN- $\alpha$ 2a (with sub-

sequent resumption at 33% of the starting dose); grade IV = permanent discontinuation of either drug.

### Statistical analysis

The design of this 3-arm phase II randomised trial was based on the assumption that the response rate to first-line endocrine treatment would be approximately 40% with a median time to progression of about seven months. It was planned to enrol approximately 90 evaluable patients (about 30 patients per arm).

The  $\chi^2$  test was used to examine whether the types of response and toxicities were different in the three treatment groups; Kaplan-Meier curves were used to describe the time to progression and overall survival.

Three post-study hypotheses were postulated: the activation of a phase III randomised study comparing

TAM and TAM + RA if the latter proved to be better than TAM, with no grade 3-4 toxicity; the activation of a phase III randomised study comparing TAM and TAM + IFN- $\alpha$ 2a if the latter proved to be better than TAM, with no grade 3-4 toxicity; the discontinuation of the study without the activation of subsequent studies in the case of treatment equality, grade 3-4 toxicity.

### Results

This study involved 99 patients (32 in arm A, 34 in arm B and 33 in arm C), 94 of whom were evaluable for response (32 in arm A, 32 in arm B and 30 in arm C); five patients were unevaluable because of insufficient treatment (2 in arm B and 3 in arm C).

Table 1 shows that the three groups were well ba-

**Table 1.** Patient characteristics

	TAM	TAM + RA	TAM + IFN- $\alpha$ 2a
Eligible	32	34	33
Performance status (ECOG)			
0-1	30	27	32
2-3	2	7	1
Menopause			
Postmenopause $\leq$ 60 years	20	16	16
Postmenopause >60 years	12	18	17
Disease-free interval			
None	1	5	9
$\leq$ 2 years	4	5	5
>2 years	27	24	19
Dominant site			
Soft tissue	11	10	11
Bone	11	13	12
Viscera	10	11	10
Estrogen receptors			
Positive	10	15	15
Unknown	24	19	18
PRogesterone receptors			
Positive	10	11	13
Unknown	24	23	20
Previous adjuvant therapy			
Yes	19	19	18
No	13	15	15
Previous chemotherapy for advanced disease			
Yes	4	6	1
No	28	28	32

**Table 2.** Response (intention-to-treat analysis)

	TAM	TAM + RA	TAM + IFN- $\alpha$ 2a
Patients	32	34	33
Insufficient treatment	0	2	3
Progression	10	12	8
Stable disease	8	7	8
Partial response	9 (28%)	11 (32%)	10 (30%)
Complete response	5 (16%)	2 (6%)	4 (12%)
Complete + partial response	14 (44%)	13 (38%)	14 (42%)

lanced. Overall, the dominant site of metastasis was soft tissue in 32%, bone in 36% and viscera in 32%. Fifty-seven percent of the patients had received previous adjuvant treatments and only 11% previous chemotherapy for advanced disease; none had received endocrine therapy for advanced disease.

The overall response rate (CR + PR) at intention-to-treat analysis was 44% (95% CI: 26.8-61.2) in arm A, 38% (95% CI: 21.7-54.3) in arm B, and 42% (95% CI: 25.2-58.8) in arm C, with no significant difference among the groups; the CR rates were respectively 16% (95% CI: 3.3-28.7), 6% (95% CI: 0-13.9) and 12% (95% CI: 0.9-23.1) (Table 2).

### Survival


After a median follow-up of eight years, there was no significant between-group difference in the overall median survival: 47.4 months (95% CI: 26.8-68.0) in arm A, 38.2 months (95% CI: 18.9-57.4) in arm B, and 45.1 months (95% CI: 30.5-59.7) in arm C (Fig. 1).

The median time to progression was 13 months in arm A, 12.5 months in arm B, and 10 months in arm C.

### Toxicity

Side effects were negligible in arm A; cutaneous (39%) and mucosal toxicity (62%) were frequent in arm B; and flu-like syndrome and/or myalgia (46%) in arm C.

Most of these toxicities were grade 1-2 (Table 3).



**Figure 1.** Overall survival by treatment arm.

### Discussion

This study was started in the 1990s, when tamoxifen represented the standard endocrine treatment for patients with metastatic breast cancer. However, although third-generation aromatase inhibitors are currently the most widely used drugs in the first-line endocrine treatment of advanced breast cancer (17-22), tamoxifen still plays a fundamental role in the disease management.

The rationale for TAM + RA or IFN- $\alpha$ 2a combinations is based on the results of preclinical studies and preliminary clinical experiences indicating that

**Table 3.** Toxicity

	TAM	TAM + RA	TAM + IFN- $\alpha$ 2a
Patients	32	34	33
Leukopenia			
Grade 1-2	3 (9%)	1 (3%)	6 (18%)
Grade 3-4	-	-	-
Anemia			
Grade 1-2	2 (6%)	1 (3%)	3 (9%)
Grade 3-4	-	-	-
Vomiting			
Grade 1-2	3 (9%)	1 (3%)	8 (24%)
Grade 3-4	-	-	1 (3%)
Flu-like syndrome			
Grade 1-2	2 (6%)	-	13 (39%)
Grade 3-4	-	-	-
Mucositis			
Grade 1-2	-	20 (59%)	1 (3%)
Grade 3-4	-	2 (6%)	-
Myalgia			
Grade 1-2	-	5 (15%)	1 (3%)
Grade 3-4	-	-	1 (3%)
Skin toxicity			
Grade 1-2	-	15 (44%)	1 (3%)
Grade 3-4	-	6 (18%)	-
Alopecia	-	1 (3%)	-
Metrorrhagia	1 (3%)	1 (3%)	-
Hot flushes	3 (9%)	-	1 (3%)

they might be more effective than TAM alone (1-14). In particular, Pozzolt et al. (13) treated three patients with TAM 30 mg/day combined with subcutaneous IFN- $\alpha$  3 MU/day (the IFN- $\alpha$  dose was reduced to 3 MU twice a week because of the onset of leukopenia in two patients), and one experienced an extremely long partial remission lasting 59 months. In another study, Recchia et al. treated 20 patients with metastatic breast cancer refractory to conventional therapy with a combination of TAM plus intravenous retinol palmitate and subcutaneous INF- $\beta$  1 MU/day thrice weekly, and observed seven complete and five partial responses (14).

However, our results show that the two experimental treatments are not superior to conventional TAM therapy; furthermore, the patients in the two

combined treatment arms experienced more side effects.

From the patients' characteristics, the lack of knowledge of receptor status can be noted; this can be explained by the fact that this procedure was not routinely performed in the 90's; however the three groups were well balanced.

On the basis of our findings, the combination of TAM with RA and/or IFN cannot be recommended in women with metastatic breast cancer.

## References

1. Lacroix A, Lippman MF, et al. Binding of retinoids to human breast cancer cell lines and their effect on cell growth. *J Clin Invest* 1980; 65: 586-91.

2. Wetherall NT, Taylor CM, et al. The effects of retinoid treatment and antiestrogens on the growth of T 47 D human breast cancer cells. *Eur J Cancer Clin Oncol* 1986; 22: 53-9.
3. Sporn MB, Roberts AB, Wakefield LM, Glick AB. Growth factors and retinoids in suppression of neoplasia. *Cancer Res* 1990; 31: 463.
4. Cassidy J, Lippman M, Lacroix A, Pecks G. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. *Eur J Cancer Clin Oncol* 1982; 18: 925-8.
5. Muss HB, Kempf RA, Martino S, et al. A phase II study of recombinant alfa interferon in patients with recurrent metastatic breast cancer. *J Clin Oncol* 1984; 2: 1012-6.
6. Barreras L, Vogel CL, Koch G, Marcus SG. Phase II trial of recombinant beta (IFN-beta) interferon in the treatment of metastatic breast cancer. *Investigational New Drugs* 1988; 2: 211-5.
7. Sherwin SA, Mayer D, Ochs JJ, et al. Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. *Ann Int Med* 1983; 98: 598-602.
8. Muss HB, Caponera M, Zecan PJ, et al. Recombinant gamma interferon in advanced breast cancer: a phase II trial. *Investigational New Drugs* 1986; 4: 377-81.
9. Sarna GP, Figlin RA. Phase II trial of alfa-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. *Cancer Treat Rep* 1985; 69: 547-9.
10. Brunsch U, Groos G, Tigges FJ, et al. Lack of response in nine patients with breast cancer treated with fibroblast interferon. *Cancer Chemother Pharmacol* 1984; 13: 39-42.
11. Borden EC, Holland HF, Dao TL, et al. Leukocyte-derived interferon alpha in human breast cancer. *Ann Intern Med*; 97: 1-6.
12. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. *Ann Int Med* 1980; 93: 399-406.
13. Pozzolt F, Otto AM, Trauschel LB, et al. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. *J Cancer Res Clin Oncol* 1989; 115: 465-9.
14. Recchia F, Morgante A, Ercole C, et al. Differentiation induction and Tamoxifen therapy for stage IV breast cancer. Preliminary report of a phase II study. *Proceed. ASCO* 1990; 9: 50.
15. Di Blasio B, Dalla Chiesa M, Franciosi V, et al. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon a-2a as first-line endocrine treatments in advanced breast cancer: results of a phase III prospective randomised multicentric trial. *Annals of Oncology* 2002; 13, suppl. 3, abstr A56.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. *Cancer* 1981; 47: 207-14.
17. Bonnetterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus Tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. *J Clin Oncol* 2000; 18: 3748-57.
18. Nabholz JM, Budzar A, Pollak W, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. *J Clin Oncol* 2000; 18: 2758-3767.
19. Milla-Santos A, Milla L, Rallo L, Solana V. Anastrozole vs. tamoxifen in hormonodependent advanced breast cancer: a phase II randomized trial. *Breast Cancer Research Treatment* 2000; 64: abstract 173.
20. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer group. *J Clin Oncol* 2001; 19: 2596-606.
21. Mouridsen H, Sun Y, Gershanovich M, et al. Final survival analysis of the double-blind, randomised multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. *Breast Cancer Research Treatment. Special Issue: 24<sup>th</sup> Annual San Antonio Breast Cancer Symposium* 2001; 69: 211. Abstract 9.
22. Paridaens R, Dirix L, Lohrisch C, et al. Activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (PTS): final results of an EORTC randomized phase II trial. *Breast Cancer Research Treatment* 2000; 64: Abstract 167.

Accepted: 23th October 2007

Correspondence: Matteo Dalla Chiesa, MD  
Oncology Division, Istituti Ospitalieri of Cremona  
Viale Concordia 1, 26100, Cremona, Italy  
Tel. 0039-0372-405248  
Fax 0039-0372-405702  
E-mail: mdallachiesa@yahoo.it; www.actabiomedica.it